Introduction
Dystonia is a disorder that causes involuntary contraction of skeletal muscles, abnormal posture, and severe pain or discomfort. Dystonia may be more common than evidence suggests, owing to under-recognition, misdiagnosis, or late clinical presentation.
Conventional therapeutic options for CD include skeletal muscle relaxants, anticholinergics, and rehabilitative therapy. In addition, some patients need deep brain stimulation therapy and selective peripheral denervation. 4 Pharmacotherapy involving botulinum neurotoxin type A (BoNT-A) injection has also proven effective 11, 12 for CD, especially when combined with conventional therapy. By reducing muscle force, such treatment can alleviate pain, increase the range of free movement, and improve resting posture. Consequently, BoNT-A therapy can reduce the everyday care burden of managing CD 13 and also improves patients' and potentially, caregivers' quality of life (QoL). BoNT-A usage for CD has also been shown to result in productivity-related gains through decreased absenteeism and sickness leave. 14 Also, another study found that, compared with patients on oral medications, more of those on BoNT-A treatments had improvement in employment status (oral medications: 18.5%; BoNT-As: 66.1%) and restoration of full employment with normal productivity (oral medications: 0%; BoNT-As: 12.9%). 15 Such results may reflect BoNT-As' ability to reduce pain and bring about functional improvements in patients with CD, given the strong association between pain and physical dysfunction with job impairment. 16 These findings invite questions about the comparative effects of the various BoNT-As available. Currently, three such products are used for CD in the UK: abobotulinumtoxinA (Dysport ® : Ipsen Limited, Slough, UK), onabotulinumtoxinA (Botox ® : Allergan Limited, Marlow, UK), and incobotulinumtoxinA (Xeomin ® : Merz Pharmaceuticals GmbH, Frankfurt/Main, Germany). Of note, although no published head-to-head trials have compared the effectiveness of these BoNT-As, a recent mixed treatment comparison reported similar improvements in scores on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS; which comprises three independently scored subscales [severity, disability, pain] , with the three scores being summed to give the TWSTRS total score [range 0-87, best to worst] 17 ). 18, 19 However, evidence also suggests that these BoNT-As differ in key characteristics, including time to first improvement, maximum benefit derived by patients, duration of symptomatic relief, and costs. 8, 20 This lack of clarity about the relative merits of different BoNT-As in CD is echoed by other key unknowns regarding these drugs. In particular, despite the significant costs of CD to the UK National Health Service(NHS), 8 there are no published UK data on the associated productivity losses of patients not treated with BoNT-As nor on the cost-effectiveness of these treatments. Little or no evidence exists on cost-effectiveness of BoNT-As for CD in the UK, although one study 21 showed BoNT-As to be cost-effective over a 1-year time horizon relative to BSC from the US government perspective.
With such data gaps in mind, we used economic modeling to assess the cost-effectiveness of abobotulinumtoxinA and other BoNT-As versus best supportive care (BSC) as treatment for CD, from the perspective of the UK NHS and Personal Social Services (PSS). For these purposes, BSC comprised oral medications (including benzodiazepines, baclofen, and anticholinergic agents), deep brain stimulation, and selective peripheral denervation.
Methods Overview
Ethical permission was not required for this study as it was based purely on secondary data. A Markov model 22, 23 with a 3-month cycle duration was developed in Microsoft Excel ® (2010) to predict the costs, benefits, and incremental costeffectiveness ratios (ICERs) per life-year and quality-adjusted life-year (QALY) from initiation of BoNT-A therapy or BSC over an analytic time horizon (lifetime in base case; varied in scenario analyses) or until death. The analysis adopted the perspective of the UK NHS and PSS. Model costs and outcomes were discounted at 3.5% per annum based on the National Institute for Health and Care Excellence reference case. 24 The currency year for the analyses was 2013. Key characteristics of the population in the model were intended to closely match those in an abobotulinumtoxinA trial. 25 In this study, the mean age was 53.0 years (standard deviation [SD]: 13.0 years); 37% were males and the mean baseline total TWSTRS score was 44.9 (SD: 8.4). As there is no evidence that CD increases mortality risk, the model calculated age-specific mortality using interim life tables from the UK Office for National Statistics. 
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Cost-effectiveness analysis of abobotulinumtoxinA Model structure Figure 1 presents the model structure for the BoNT-A and BSC arms, which was informed by consultation with clinical experts. In the BoNT-A arm, patients with CD starting active treatment are divided into two health states: "no response" or "response." Response was defined as an improvement in TWSTRS from baseline of at least 20% at week 4 or 8 or 12, in the base case (higher improvement in TWSTRS from baseline (≥30%) has been tested as part of alternative scenario analysis). Owing to unavailability of data, it was assumed that patients not responding to the initial injection do not achieve response in subsequent injection cycles. Similarly, patients who respond to the initial injection are assumed not to develop secondary nonresponse. Accordingly, only the first injection cycle determines the number of responding and nonresponding patients throughout the model. In an alternative scenario, the model assumed that nonresponders could achieve response with subsequent reinjections given at higher doses. Before treatment discontinuation, nonresponders are allowed up to six BoNT-A reinjections (with electromyographic or ultrasound guidance) before moving to BSC. Initial responders were allowed to receive up to four reinjections before becoming secondary nonresponders and may require investigations (a frontalis or anti-BoNT-A antibody titer test) to determine whether they are resistant to the BoNT-A, before they move to BSC. The enforced discontinuation after these cycles of nonresponse is modeled using tunnel states in the Markov design. Additionally, patients receiving BoNT-A may discontinue treatment due to causes such as loss of effect, severe adverse events (AEs), or other reasons according to an annual discontinuation rate. Once patients discontinue treatment, they move on to BSC. At all health states, patients can die. In the nonactive treatment (BSC) arm, patients start and remain in BSC state until death.
Dysphagia is a commonly reported AE that may impair the patient's QoL or carry certain management costs. Disutility and costs associated with dysphagia were included in the model for the proportion of patients who experience it, but it was assumed not to cause treatment discontinuation.
Model inputs

Efficacy inputs
Data on clinical efficacy (improvements in TWSTRS) were derived from the Phase III placebo-controlled trial ClinicoEconomics and Outcomes Research 2017:9 submit your manuscript | www.dovepress.com
Dovepress
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Muthukumar et al of abobotulinumtoxinA (NCT00288509). 25 In this study, compared with placebo, a abobotulinumtoxinA produced significant decreases from baseline in the mean TWSTRS total scores compared with placebo at week 4 (−15.6, SD: 2.0 vs −6.7, SD: 2.0; p<0.001) with significant improvements sustained to week 12 (−9.1, SD: 1.7 vs −4.9, SD: 1.7; p=0.019). 25 The model assumed that within a model cycle, which was set to be equal to one injection cycle, responders to BoNT-A could experience a sharp improvement in the total TWSTRS score by week 4, with this peaking at week 8, and then waning by week 12. It also assumed that the TWSTRS score at the end of each cycle did not return fully to the baseline value due to residual benefit from BoNT-A as shown in Figure S1 . It was also assumed that patients on BSC could benefit from minor improvements in TWSTRS compared to baseline.
Other clinical inputs such as reinjection interval, annual rate of all-cause treatment discontinuation, and AE rates for dysphagia per injection are given in Table S1 , with corresponding assumptions.
Utility inputs
For the model, death was assigned a utility of 0 and 1 represented a state of perfect health. Utility data were derived from the Phase III trial of abobotulinumtoxinA. 25 Specifically, the relationship between TWSTRS and utility was determined using a repeated-measures logistic regression analysis on the 36-item Short Form Health Survey and TWSTRS data at baseline or week 12 (Table S2, Figure 2) . A preference-based value set was applied to patient responses to the 36-item Short Form Health Survey to obtain utilities. In the model, utility was linked at all times to the TWSTRS score such that improvement or worsening of TWSTRS corresponded with an increasing or decreasing utility. The calculated baseline utility and utility gains at weeks 0, 4, 8, and 12 are detailed in Table 1 . 
Notes:
The line represents the best fit to the available data given by the blue points showing reduced utility with higher TWSTRS total score. Abbreviation: TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale. 
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Resource use and cost inputs
Direct medical costs in the model comprised the value of all goods, services, and other resources involved in providing the intervention and all current and future consequences linked to the disease process. These included primarily drug costs, administration costs, and disease management costs as outlined in Table 2 . All other resources used, concomitant medication costs, and unit costs are detailed in Table S1 .
In particular, the model assumed that the drug dose varied between first injection and reinjections, as well as among health states with different response levels (nonresponders and responders). Reinjections were associated with a higher dose than first injection, as real-world treatment patterns indicate that doctors normally start with the lowest dose and increase it gradually in subsequent injections if the patient does not respond. Consequently, nonresponders have a higher average dose than responders. Model inputs for first injection were obtained from the summary of product characteristics (SmPC) for each BoNT-A, 27-29 while doses and treatment intervals for subsequent injections were those suggested by clinical experts.
Drug administration costs were incurred for each injection according to the health care professional who gave the BoNT-A injection and the frequency of treatments.
Concomitant medication costs were incurred for medications used by patients with CD in addition to BoNT-A therapy. Disease management costs comprised those of hospitalizations, surgery, or health care professional visits required additionally to those for BoNT-A administration.
Indirect costs primarily included costs associated with productivity losses of patients with CD. To quantify the economic impact of productivity losses, lost productive time (LPT) from Stacy et al (2012) 30 was used to estimate the perperson hours per week associated with reduced performance at work ("presenteeism") and absence from work ("absenteeism") due to disability. The associated indirect costs per week were estimated by multiplying the LPT by the average hourly income in the UK (given in Table S1 ). Due to unavailability of data, indirect costs for time to doctor office visits and for caregivers' time were not considered.
Analyses Base-case analysis
The base-case analysis compared the costs and QALYs, discounted at 3.5%, of using abobotulinumtoxinA versus BSC, from the NHS and PSS perspective over a lifetime horizon in a scenario where response is considered as at least 20% improvement in TWSTRS total score from 
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Muthukumar et al baseline and vial-sharing was not allowed. The base-case model parameters are presented in Table S1 alongside their assumptions, with the exception of indirect costs, which were considered only in an alternative scenario analysis described ahead.
Alternative scenario analysis
Alternative scenario analyses were conducted to test the following assumptions: productivity losses incurred by patients with CD; sharing of vials; analytic time horizon of 5 years; injection cycles as in the SmPCs, specifically, 16 weeks for abobotulinumtoxinA, 28 10 weeks for incobotulinumtoxinA, 29 10 weeks cycle for onabotulinumtoxinA 27 ; at least 30% improvement in TWSTRS from baseline and allowance of secondary nonresponse following the initial BoNT-A injection, or achievement of response at subsequent injection cycles for initial nonresponders. The following comparisons were also performed: onabotulinumtoxinA versus BSC; incobotulinumtoxinA versus BSC; abobotulinumtoxinA versus onabotulinumtoxinA; and abobotulinumtoxinA versus incobotulinumtoxinA.
One-way sensitivity analysis
To identify model drivers and examine key areas of uncertainty within the model, one-way sensitivity analyses were provided for all major model variables. Parameters were varied between a minimum and maximum range that was determined directly from published data. Where data were not available to inform this range, the minimum and maximum values were ±20% of the base-case value. Tornado diagrams were generated for incremental costs, incremental QALYs and ICERs, and incremental net benefit using a £20,000/ QALY threshold. Table S3 lists the parameters varied in one-way sensitivity analysis.
Probabilistic sensitivity analysis
To account for multivariate and stochastic uncertainties in the model, a probabilistic sensitivity analysis was performed. Probabilistic parameters were defined according to appropriate statistical distributions to ascertain uncertainty. The selection of distributions was dependent on the nature of the underlying parameter, with beta distribution being used for probabilities and utilities, and gamma distribution used for positively valued parameters such as the costs.
The probabilistic sensitivity analysis was run for 5,000 simulations. The incremental gains in terms of QALYs were plotted against incremental costs of abobotulinumtoxinA and its comparators on the cost-effectiveness plane. A costeffectiveness acceptability curve was generated to show the probability of being cost-effective for each treatment over a range of willingness-to-pay values for a QALY. Table S4 lists the distribution of parameters varied in probabilistic sensitivity analysis.
Results
Base-case results
The discounted costs and health outcomes for abobotulinumtoxinA and BSC for the base case are given in Table 1 . The total incremental QALYs gained from abobotulinumtoxinA compared to BSC was 0.235 per patient, with the total incremental cost being £7,160. This corresponds to an ICER of £30,468 per QALY gained.
Alternative scenario results
The results of abobotulinumtoxinA versus BSC for the alternative scenarios are presented in Table 3 . With vial-sharing, the total incremental QALYs gained were unchanged but the associated total incremental costs were £6,234, corresponding to an ICER of £26,526 per QALY (i.e., lower than the base-case ICER). When productivity losses were considered, the QALYs remained unchanged but the total incremental costs were -£7,311, implying that abobotulinumtoxinA usage was cost-saving compared to BSC. Changing the time horizon to 5 years resulted in total incremental costs of £2,809, incremental QALYs of 0.083, and an ICER of £38,117. Considering 5% secondary nonresponders and 25% secondary responders resulted in total incremental QALYs of 0.247, total incremental costs of £10,072, and an ICER of £40,777. With a 16-week reinjection interval for abobotulinumtoxinA, 28 the incremental costs and QALYs were found to be £5,396 and 0.252, respectively, with an associated ICER of £21,413. Considering response as 30% improvement in TWSTRS from baseline resulted in an ICER of £29,089 (i.e., lower than the base-case ICER). Table S5 presents comparisons of onabotulinumtoxinA and incobotulinumtoxinA versus BSC and abobotulinumtoxinA versus onabotulinumtoxinA and incobotulinumtoxinA for 12-and 10-week reinjection intervals. Compared to BSC, the ICERs for onabotulinumtoxinA and incobotulinumtoxinA were £48,978 and £58,554 for the 12-week injection cycle, and £48,625 and £44,933 for the 10-week interval, respectively, due to higher drug-acquisition costs associated with onabotulinumtoxinA and incobotulinumtoxinA compared to abobotulinumtoxinA.
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One-way sensitivity analysis results
One-way (deterministic) sensitivity analysis was conducted on the parameters listed in Table S3 . The tornado diagrams given in Figures S2-S5 show the most influential parameters on outcomes for abobotulinumtoxinA versus BSC. Incremental costs were most influenced by the proportion of responders to abobotulinumtoxinA at first injection, duration of the reinjection interval, and the number of cycles of reinjection allowed among primary nonresponders. Incremental QALYs and incremental net benefit were most sensitive to number of cycles of reinjection allowed amongst primary nonresponders and proportion of responders and nonresponders to abobotulinumtoxinA at first injection. ICERs were most sensitive to TWSTRS value at baseline among BSC and abobotulinumtoxinA patients and the number of cycles of reinjection allowed among primary nonresponders.
Probabilistic sensitivity analysis results
Results of the probabilistic sensitivity analysis conducted for the base case are presented in Figures 3 and 4 . The costeffectiveness plane shows that, although abobotulinumtoxinA is more costly than BSC, it is also more effective. The CEAC showed that abobotulinumtoxinA had a 46% probability of being cost-effective at a threshold of £20,000 compared to BSC without BoNT-A injections. 
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Discussion
Our economic model showed for patients with CD in the UK that abobotulinumtoxinA was cost-effective compared to BSC, at a maximum acceptable willingness-to-pay threshold of £30,000 per QALY 24 under base-case assumptions. Specifically, the treatment provided a lifetime gain of 0.235 QALYs at an incremental cost of £7,160 and the health benefits was attributable to a reduction in the severity of CD (as measured by TWSTRS, which correlated directly with patients' utility). In addition, the results remained broadly consistent in both testing of alternative scenarios to the base cases and across a range of sensitive analyses. Overall, therefore, our findings represent a significant development in the knowledge of the economic and health benefits of using BoNT-As for this indication, given that few other economic evaluations of these treatments for CD have been previously published. 21, 31 As with many models, ours had limitations arising from data availability and structural assumptions. In terms of clinical response, data were available to estimate the proportion of responders and their improvement in TWSTRS total score for the first injection cycle from clinical trial 25 but not for subsequent cycles. Therefore, it was assumed that only the first injection determined response, although in clinical practice additional responses would probably be achieved in subsequent cycles for more patients. Furthermore, there was a lack of data on the quantities of abobotulinumtoxinA administered and health care resources consumed in managing patients. We made the assumption that the utility-TWSTRS relationship, which was estimated based on data from one cycle of botulinum toxin use, would apply equally to subsequent cycles, though we cannot know how this relationship may differ at later times. Having to extrapolate outcomes beyond the timeframe of available clinical data was another unavoidable limitation -one commonly encountered in this type of evaluation. A key strength of our study is how it took account of productivity gains resulting from effective treatment for CD. The importance of CD's effect on productivity has been recognized previously, although studies have not generally quantified it suitably for subsequent use in economic evaluations. For instance, a study of almost 300 patients by the Finnish Dystonia Association 32 found 97 subjects (39%) had retired because of CD at a median age of 48 years, while many others reported sick leave, reduced productivity, and loss of employment. 14, 33 Similarly, a second study found 53.3% of patients with CD reported that employment status was negatively affected through reduced hours or responsibilities, including 18.9% of patients who had lost employment due to CD symptoms. 15 Another reason that is essential to demonstrate the cost-effectiveness of BoNT-A is that many patients receive inappropriate treatment (e.g., physiotherapy alone), given that CD is an under-recognized condition and BoNT-As are consequently underutilized for CD. To the extent that cost of treatment with BoNT-A is a potential barrier, it is important to communicate the cost-effectiveness of BoNT-A. In conclusion, we believe that in demonstrating the cost-effectiveness of abobotulinumtoxinA as treatment for CD, our study makes a compelling case for wider use in the UK of such therapy that can benefit patients with this physically and psychologically debilitating condition.
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Conclusion
The use of abobotulinumtoxinA in adult patients with CD was found to be cost-effective at an acceptable willingnessto-pay threshold in the UK and also provided additional QoL gains. This evidence should help to inform clinical decision making and commissioning where BoNT-A therapy is being considered as a potential treatment for CD.
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